31 results about "Herpes Labialis" patented technology

The invention relates to the technical field of biology, and discloses anti-herpes simplex virus polypeptide and its application. Tests show that the anti-herpes simplex virus polypeptide has a high efficiency inhibition effect to the herpes simplex virus propagation, and the anti-herpes simplex virus polypeptide is used for producing the medicines for treating and preventing diseases related to herpes simplex. The invention provides a medicinal preparation which takes the anti-herpes simplex virus polypeptide as the effective component for treating the herpes caused by the herpes simplex virus, and has a obvious effectiveness for treating herpes, the effective rate for treating herpes simplex, labial herpes and genital herpes can reach to 100%. And the anti-herpes simplex virus polypeptide has low recurrence rate after heal and no toxic side effect.

The invention provides a compound preparation used for preventing and treating oral cavity diseases of pets. The compound preparation comprises: lysozyme, glycine, aspartic acid, Vitamin B1 nitrate, Vitamin B2, menthol and montmorillonite according to the weight ratio of: 0.03-0.15 parts of the lysozyme, 0.30-1.5 parts of the glycine, 0.12-0.28 parts of the aspartic acid, 0.012-0.028 parts of theVitamin B1 nitrate, 0.03-0.07 parts of the Vitamin B2, 0.12 parts of the menthol, and the montmorillonite is added to 12 parts. The compound preparation can be extensively applied to treatment on diseases of injury, inflammation or ulcer on mouth mucosa, gingiva and lips, herpes labialis, false teeth base plate pressure sores and the like of cats and dogs in all ages. The compound preparation canbe adhered to an affected part for relieving pain and promoting healing of the affected part, and also can be used as a dressing after exodontias and odontolith scaling, and also can used for treatingangular cheilitis, thick and white tongue coating and bad breath.

The present invention is generally directed toward therapeutic compositions for treating infections caused by Herpes Simplex Virus (“HSV”). The therapeutic compositions meet a long felt need in the art of providing a treatment for lesions that result from HSV that drastically reduce the duration of a cold sore when vesicles have already appeared and a treatment that will prevent the outbreak of a lesion and formation of vesicles when applied in the prodormal stage. The therapeutic compound comprises a mixture of Acyclovir (“ACV”), Penciclovir (“PCV”), and 2-Deoxy-D-Glucose (“2-DDG”). The therapeutic compositions of the present invention include multiple formulations of the three active ingredients and may also include inactive ingredients.

A method of treating Herpes Labialis includes assembling a patch having hydrocolloid particles added to a layer of adhesive to so configure the patch to have a limited absorption of moisture into the patch combined with a permeability of moisture through and out of the patch. The method additionally includes providing the patch to the user and having the user apply the patch to the user's face in treating the Herpes Labialis, and configuring the patch to be less visible when applied to the user's face than a cream is visible when applied to the user's face.

The invention relates to a method for using alcaine 13-hexyl berberine and relative alcaine 13-hexyl palmatine to prepare the drug that treats herpesvirus infection on skin mucosa. And said two compounds have strong functions to resist HSV, I, II herpesvirus. And their restrain density (IC50) of external resist HSV-1 type and HSV-2 type is 0.78-1.56 mug / ml. And the 0.5% 13-hexyl berberine or alcaine 13-hexyl palmatine, or 1% emulsion can treat bleb, stronger than 3% assili lovou.

The present invention relates to a topical film-forming composition including, in a pharmaceutically acceptable medium: 5 to 30 wt % of ethyl cellulose; 0.1 to 10 wt % of an auxiliary film-forming agent; 0.1 to 20 wt % of one or more triacids, at least one of which is boric acid; and 60 to 95 wt % of an organic solvent, the percentages being expressed by weight relative to the total weight of the composition. The invention also relates to the use of such a composition in a method for treating herpes, in particular herpes labialis.

The present invention is generally directed toward therapeutic compositions for treating infections caused by Herpes Simplex Virus (“HSV”). The therapeutic compositions meet a long felt need in the art of providing a treatment for lesions that result from HSV that drastically reduce the duration of a cold sore when vesicles have already appeared and a treatment that will prevent the outbreak of a lesion and formation of vesicles when applied in the prodromal stage. The therapeutic compound comprises a mixture of Acyclovir (“ACV”), Penciclovir (“PCV”), and dimethyl sulfoxide (“DMSO”). The therapeutic compositions of the present invention include multiple formulations of the three active ingredients and may also include inactive ingredients and / or additional active ingredients.

The invention discloses a traditional Chinese medicine composition for treating herpes labialis and a preparation method thereof. The traditional Chinese medicine composition is prepared from, by weight, 11-19 parts of radix scutellariae, 15-25 parts of fructus forsythiae, 10-20 parts of fructus gardeniae, 14-22 parts of radix asparagi, 8-16 parts of rheum officinale, 6-13 parts of lemon grass, 10-20 parts of poria cocos, 7-14 parts of rhizoma alismatis, 15-25 parts of honeysuckle flowers, 16-24 parts of licorice roots, 9-18 parts of radix rehmanniae, 7-14 parts of rhizoma coptidis, 12-23 parts of medulla junci, 10-20 parts of medulla tetrapanacis, 8-16 parts of cortex phellodendron Chinese, 15-25 parts of bitter gourd seeds, 18-26 parts of sophora flowers, 9-18 parts of radix scrophulariae and 10-20 parts of rhizoma anemarrhenae. The traditional Chinese medicine composition is prepared from radix scutellariae, fructus forsythiae, fructus gardeniae, radix asparagi, rheum officinale, lemon grass, medulla junci, medulla tetrapanacis, cortex phellodendron Chinese, bitter gourd seeds and sophora flowers through scientific compatibility, can achieve the effects of clearing away heat and toxic materials, dispelling wind and purging fire, clearing away the heart-fire and heat, nourishing yin for lowering fire and guiding fire to origin through the synergistic effect of the raw materials, can be effectively used for treating the herpes labialis and is exact in treatment effect, good in treatment effect, capable of rapidly achieving the effects and short in treatment cycle, and the effective rate reaches 95% or above.

The invention belongs to the technical field of wet tissues and application thereof and specifically relates to preparation and application of a novel interferon alpha-2b wet tissue. The novel interferon alpha-2b wet tissue provided by the invention comprises medicine liquid and a carrier carrying the medicine liquid, wherein the medicine liquid contains interferon alpha-2b, a protein stabilizer and water, and the mass ratio of the protein stabilizer to interferon alpha-2b is 1: (4-20), preferably 1: (4-10) and more preferably 1: 4. The invention solves the problem of bioactivity of interferon alpha-2b in the interferon alpha-2b wet tissue and creates a wet tissue containing interferon alpha-2b; and furthermore, the wet tissue containing interferon alpha-2b can be applied to auxiliary treatment of viral infection type skin diseases, such as herpes labialis, herpes zoster, genital herpes, genital warts and the like, and can well solve various disadvantages of various conventional methods for treating viral infection type diseases.

The present invention pertains generally to the field of therapy, and more specifically to the field of therapy for herpes simplex and herpes zoster, and more particularly, to methods of reducing the rate of relapse, delaying relapse, and / or preventing relapse of herpes labialis (cold sores on the lips), herpes genitalis (genital herpes), and herpes zoster (shingles, zona), by topical administration of polyethylene glycol (PEG), or a composition comprising PEG.

The invention discloses a lipstick assisting in treatment of herpes labialis and a preparing method thereof. The lipstick assisting in treatment of herpes labialis is mainly prepared from honeysuckle flower, radix puerariae, licorice root, menthol, beewax, vaseline, arnebia root oil and wool fat. The lipstick can be used for assisting in treatment of herpes labialis, lip dryness and crack as well as oral infection. The lipstick has a good moistening effect and anti-crack effect.

The invention discloses a traditional Chinese medicine pressurized spray for treating skin disorders or mucosa orifice diseases. The pressurized spray is prepared from the following raw material medicines in parts by weight: 250 to 500 parts of herba euphorbiae humifusae, 50 to 250 parts of cortex dictamni, 50 to 250 parts of clove, 25 to 175 parts of tokyo violet herb, 25 to 175 parts of rhizoma dryopteris crassirhizomae, 25 to 175 parts of purslane and 5 to 50 parts of borneol. The invention also provides a detection method thereof. The method comprises the following steps: using a thin-layer chromatography to qualitatively identify the herba euphorbiae humifusae, the clove, the tokyo violet herb and the cortex dictamni, and using an HPLC (high performance liquid chromatography) to determine the content of the herba euphorbiae humifusae. The pressurized spray provided by the invention has unique curative effects on early stage pain and after pain of herpes. The preparation has the efficacies of clearing heat and removing toxicity, dispelling wind and arresting itching and activating meridians to stop pain. The preparation has stronger actions of antivirus and broad-spectrum antibacterial. The pressurized spray can be used for treating various skin and mucosaorifice diseases, such as herpes zoster, herpes labialis, varicella, beriberi, vaginitis and the like.

The present invention provides a medicament, in particular, a novel compound for preventing or treating various infections caused by herpesviridae viruses, especially infections caused by various herpes viruses, such as those caused by varicella zoster virus. Varicella (chickenpox), varicella zoster caused by multiple infections of latent varicella-zoster virus, cold sores and herpes encephalitis caused by HSV-1 infection, and genital herpes caused by HSV-2 infection. The present invention provides N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carbamoyl derivatives and salts thereof, wherein, phenyl The 4-position is substituted by a specific 5- or 6-membered heteroaryl group, it has effective antiviral activity, and it can be administered orally at a low dose to treat the above-mentioned diseases.

A composition for the treatment of Herpes Labialis which contains CTC-96 as the active ingredient is disclosed. Methods for using the composition are also disclosed. The composition may be used as a topical ointment.

The invention relates to the technical field of biology, and discloses anti-herpes simplex virus polypeptide and its application. Tests show that the anti-herpes simplex virus polypeptide has a high efficiency inhibition effect to the herpes simplex virus propagation, and the anti-herpes simplex virus polypeptide is used for producing the medicines for treating and preventing diseases related to herpes simplex. The invention provides a medicinal preparation which takes the anti-herpes simplex virus polypeptide as the effective component for treating the herpes caused by the herpes simplex virus, and has a obvious effectiveness for treating herpes, the effective rate for treating herpes simplex, labial herpes and genital herpes can reach to 100%. And the anti-herpes simplex virus polypeptide has low recurrence rate after heal and no toxic side effect.

The present invention relates to a topical film-forming composition, which comprises in a pharmaceutically acceptable medium: 5-30wt% of ethyl cellulose; 0.1-10wt% of an auxiliary film-forming agent; 0.1-20wt% of one or A plurality of tribasic acids, at least one of which is boric acid; and 60-95% by weight of an organic solvent, the weight percentage is relative to the total weight of the composition. The invention also relates to the use of this composition in a method for the treatment of herpes, especially cold sores.